Codexis (CDXS) Cash from Investing Activities (2010 - 2026)
Codexis' (CDXS) quarterly Cash from Investing Activities came in at -$1.1 million in Q1 2026, down 109.44% year-on-year from $11.8 million in Q1 2025, and down 119.45% quarter-over-quarter from $5.7 million in Q4 2025.
Codexis (CDXS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Codexis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 109.44% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was $10.6 million, a 163.8% increase from a year earlier, with the FY2025 full-year figure at $23.5 million, up 141.25% from the prior year.
- Cash from Investing Activities eased to -$1.1 million in Q1 2026 per CDXS's latest filing, from $5.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $11.8 million in Q1 2025 and bottomed at -$28.6 million in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$1.1 million (2026), against an average of -$3.1 million.
- Across the five-year window, Cash from Investing Activities jumped 3245.45% in 2023 and slumped 1624.19% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $33000.0 in 2022, then soared by 3245.45% to $1.1 million in 2023, then plunged by 359.33% to -$2.9 million in 2024, then soared by 299.55% to $5.7 million in 2025, then slumped by 119.45% to -$1.1 million in 2026.
- Per Business Quant, the three latest CDXS Cash from Investing Activities figures stand at -$1.1 million (Q1 2026), $5.7 million (Q4 2025), and $6.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Codexis | 141.60 Mn | 76.46 Mn | 13.18 Mn | -1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.11 Mn |
| Mar 31, 2026 | -1.11 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Dec 31, 2025 | 5.71 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Sep 30, 2025 | 6.39 Mn |
| Jun 30, 2025 | -367,000.00 |
| Jun 30, 2025 | -367,000.00 |
| Mar 31, 2025 | 11.77 Mn |
| Mar 31, 2025 | 11.77 Mn |
| Dec 31, 2024 | -2.86 Mn |
| Dec 31, 2024 | -2.86 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Jun 30, 2024 | -27.09 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Dec 31, 2023 | 1.10 Mn |